Abstract:Importance: Current approaches to classify the hepatotoxic potential of medications are based on cumulative case reports of acute liver injury (ALI), which do not consider the size of the exposed population. There is little evidence from real-world data (data relating to patient health status and/or the delivery of health care routinely collected from sources outside of a research setting) on incidence rates of severe ALI after initiation of medications, accounting for duration of exposure. Objective: To identify the most potentially hepatotoxic medications based on real-world incidence rates of severe ALI and to examine how these rates compare with categorization based on case reports. Design, setting, and participants: This series of cohort studies obtained data from the US Department of Veterans Affairs on persons without preexisting liver or biliary disease who initiated a suspected hepatotoxic medication in the outpatient setting between October 1, 2000, and September 30, 2021. Data were analyzed from June 2020 to November 2023. Exposures: Outpatient initiation of any one of 194 medications with 4 or more published reports of hepatotoxicity. Main outcomes and measures: Hospitalization for severe ALI, defined by either inpatient: (1) alanine aminotransferase level greater than 120 U/L plus total bilirubin level greater than 2.0 mg/dL or (2) international normalized ratio of 1.5 or higher plus total bilirubin level greater than 2.0 mg/dL recorded within the first 2 days of admission. Acute or chronic liver or biliary disease diagnosis recorded during follow-up or as a discharge diagnosis of a hospitalization for severe ALI resulted in censoring. This study calculated age- and sex-adjusted incidence rates of severe ALI and compared observed rates with hepatotoxicity categories based on cumulative published case reports. Results: The study included 7 899 888 patients across 194 medication cohorts (mean [SD] age, 64.4 [16.4] years, 7 305 558 males [92.5%], 4 354 136 individuals [55.1%] had polypharmacy). Incidence rates of severe ALI ranged from 0 events per 10 000 person-years (candesartan, minocycline) to 86.4 events per 10 000 person-years (stavudine). Seven medications (stavudine, erlotinib, lenalidomide or thalidomide, chlorpromazine, metronidazole, prochlorperazine, and isoniazid) exhibited rates of 10.0 or more events per 10 000 person-years, and 10 (moxifloxacin, azathioprine, levofloxacin, clarithromycin, ketoconazole, fluconazole, captopril, amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, and ciprofloxacin) had rates between 5.0 and 9.9 events per 10 000 person-years. Of these 17 medications with the highest observed rates of severe ALI, 11 (64%) were not included in the highest hepatotoxicity category when based on case reports. Conclusions and relevance: In this study, incidence rates of severe ALI using real-world data identified the most potentially hepatotoxic medications and can serve as a tool to investigate hepatotoxicity safety signals obtained from case reports. Case report counts did not accurately reflect the observed rates of severe ALI after medication initiation.

Acute Liver Injury After Long-Term Herbal "Liver Cleansing" and "Sleep Aid" Supplement Use

Underreporting Supplements: A Case of Drug-induced Liver Injury Due to a Testosterone Booster

LIVER INJURY INDUCED BY HERBAL AND DIETARY SUPPLEMENTS: A POOLED ANALYSIS OF CASE REPORTS

Lethal hepatocellular necrosis associated with herbal polypharmacy in a patient with chronic hepatitis B infection

Herb-induced hepatitis secondary to artemisinin: A case report

Successful corticosteroid therapy for severe liver injury secondary to herbal traditional Chinese medicine, Mega Defends X, assessed for causality by the updated RUCAM: A case report

A Hidden Cause of Hypertransaminasemia: Liver Toxicity Caused by Chelidonium Majus L. : Report of Two Cases of Herb-Induced Liver Injury and Literature Review

S4244 Acute Hepatocellular Injury Induced by Pre-Workout Supplements

Herbal and Dietary Supplement-Induced Liver Injury: A Nationwide Comparative Study

Phytotherapy-Induced Hepatocytotoxicity: A Case Report

Liver Dangers of Herbal Products: A Case Report of Ashwagandha-Induced Liver Injury

Iberogast®-Induced Acute Liver Injury-A Case Report

Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Cholestatic liver injury associated with dietary supplements: a report of five cases in active duty service members

Acute Liver Failure Induced by Provitalize: A Menopause Supplement Concocted From Herbs & Probiotics

Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury

Exploring Acute Liver Damage: Slimming Health Foods and CYP3A4 Induction

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data

Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases